{
    "clinical_study": {
        "@rank": "154892", 
        "arm_group": {
            "arm_group_label": "Androxal 25 mg", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is an open-label, randomized, single-center, single-dose, two-way crossover study\n      of the PK properties of Androxal in healthy male subjects. Twelve male subjects will each\n      receive a single dose of Androxal 25 mg in both the fed and fasting state."
        }, 
        "brief_title": "Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal", 
        "condition": "Normal Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Speak, read, and understand English or Spanish and is willing and able to provide\n             written informed consent on an IRB-approved form prior to the initiation of any study\n             procedures;\n\n          2. Male; age 18-60 with a BMI of 25-42 kg/m2 inclusive\n\n          3. No significant abnormal findings at the screening physical examination as evaluated\n             by the Investigator;\n\n          4. Normal laboratory values (or abnormal but not clinically significant) at screening as\n             determined by the Investigator;\n\n          5. Subject is willing to remain in the clinic for the screening visit and 2 overnight\n             treatment visits (approximately 36 hours for the treatment visit)\n\n          6. Must be able to swallow gelatin capsules;\n\n          7. Must be willing to remain in the clinic for the treatment visits\n\n        Exclusion Criteria:\n\n          1. Known hypersensitivity to Clomid;\n\n          2. Abnormal screening visit vital signs or clinical laboratory evaluation considered\n             clinically significant by the Investigator;\n\n          3. A hematocrit >54% or a hemoglobin >17 g/dL.\n\n          4. Subject with a significant organ abnormality or disease as determined by the\n             Investigator;\n\n          5. Any medical condition that would interfere with the study as determined by the\n             Investigator;\n\n          6. Participation in a clinical trial with investigational medication within 30 days\n             prior to study medication administration;\n\n          7. An acute illness within 5 days of study medication administration;\n\n          8. Positive urine drug screen at the screening visit;\n\n          9. Known history of HIV and/or Hepatitis B or C\n\n         10. Tobacco (nicotine products) use in the 3 months prior to the study;\n\n         11. A mental condition rendering the subject unable to understand the nature, scope, and\n             possible consequences of the study and/or evidence of an uncooperative attitude, as\n             determined by the Investigator;\n\n         12. History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary\n             embolism);\n\n         13. History of myocardial infarction, unstable angina, symptomatic heart failure,\n             ventricular dysrhythmia, or known history of QTc interval prolongation;\n\n         14. An employee or family member of an employee of the study site or the Sponsor;\n\n         15. Previous participation in a clinical study of Androxal."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146391", 
            "org_study_id": "ZA-107"
        }, 
        "intervention": {
            "arm_group_label": "Androxal 25 mg", 
            "intervention_name": "Androxal 25 mg Capsules", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Clomiphene"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 22, 2014", 
        "number_of_arms": "1", 
        "official_title": "AN OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, TWO-WAY CROSSOVER STUDY TO EVALUATE THE EFFECT OF FOOD UPON THE PHARMACOKINETICS OF ANDROXAL", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "\u2022 Cmax of a single dose of 25 mg of Androxal in male subjects in the fed state and fasted state.", 
            "time_frame": "24 hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146391"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Repros Therapeutics Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Repros Therapeutics Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}